Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022, in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the company’s highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications.
FDA Confirms Paragraph IV Patent Litigation for Tymlos (Abaloparatide)
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA
Four months later, the Massachusetts-based company has made those words prophetic, revealing that it has agreed to sell itself to two investment firms—Gurnet Point Capital of Massachusetts and Patient Square Capital of California.